                Figure 2.  Immunophenotype of PBMCs from healthy donors and NPC patients.Surface markers analysis was performed by directly immunofluorescence labeling and FACS analysis in PBMCs from healthy donors (n = 20) and NPC patients (n = 40). * P&lt;0.01

